% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • solarae solarae Apr 23, 2009 10:13 PM Flag

    VRTX Data at EASL Suggesting Telaprevir's Potential

    “Telaprevir is the only agent that has shown the possibility of achieving SVR rates in combination therapy approaching 70% in the treatment-naïve setting with a significantly shortened treatment duration when compared with current therapy, while our recently acquired polymerase compounds are showing strong early antiviral data, which may put us in a good position to shape new STAT-C combinations with telaprevir,” said Kurt Graves, Executive Vice President, Chief Commercial Officer and Head, Strategic Development of Vertex."

79.84Jun 27 4:00 PMEDT